PRECIGEN, INC.PGENEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.
PGEN Q2 FY2023 Key Financial Metrics
Revenue
$1.8M
Gross Profit
N/A
Operating Profit
$-20.4M
Net Profit
$-20.3M
Gross Margin
N/A
Operating Margin
-1153.6%
Net Margin
-1149.9%
YoY Growth
-39.3%
EPS
$-0.08
PRECIGEN, INC. Q2 FY2023 Financial Summary
PRECIGEN, INC. reported revenue of $1.8M (down 39.3% YoY) for Q2 FY2023, with a net profit of $-20.3M (down 15.2% YoY) (-1149.9% margin).
Key Financial Metrics
| Total Revenue | $1.8M |
|---|---|
| Net Profit | $-20.3M |
| Gross Margin | N/A |
| Operating Margin | -1153.6% |
| Report Period | Q2 FY2023 |
PRECIGEN, INC. Annual Revenue by Year
PRECIGEN, INC. annual revenue history includes year-by-year totals (for example, 2022 revenue was $26.9M).
| Year | Annual Revenue | |
|---|---|---|
| 2022 | $26.9M | — |
PRECIGEN, INC. Quarterly Revenue & Net Profit History
PRECIGEN, INC. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2023 | $1.8M | -39.3% | $-20.3M | -1149.9% |
| Q1 FY2023 | $1.9M | -66.4% | $-22.7M | -1228.2% |
| Q4 FY2022 | $1.8M | +110.1% | N/A | N/A |
| Q3 FY2022 | $16.7M | +401.7% | $87.4M | 522.5% |
| Q2 FY2022 | $2.9M | -23.7% | $-17.6M | -605.8% |
| Q1 FY2022 | $5.5M | -77.5% | $-19.3M | -349.2% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5M | $2.9M | $16.7M | $1.8M | $1.9M | $1.8M |
| YoY Growth | -77.5% | -23.7% | 401.7% | 110.1% | -66.4% | -39.3% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
|---|---|---|---|---|---|---|
| Assets | $335.6M | $321.2M | $259.2M | $216.0M | $241.5M | $207.5M |
| Liabilities | $261.7M | $265.6M | $116.7M | $89.7M | $57.4M | $41.3M |
| Equity | $73.8M | $55.7M | $142.5M | $126.3M | $184.1M | $166.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
|---|---|---|---|---|---|---|
| Operating CF | $-18.8M | $-7.1M | $-23.8M | $-65.0M | $-18.4M | $-15.8M |